Peer-reviewed veterinary case report
Gene therapy with magnetic delivery for treating cat fibrosarcomas
By Hüttinger, Cornelia et al.·Published in The journal of gene medicine·2008·Clinic of Small Animal Medicine, Germany·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Neoadjuvant gene delivery of feline granulocyte-macrophage colony-stimulating factor using magnetofection for the treatment of feline fibrosarcomas: a phase I trial.
- Species:
- cat
Plain-English summary
Twenty cats with fibrosarcomas (a type of cancer) received a new gene therapy treatment using a special method called magnetofection, which helps deliver a gene that boosts their immune response. They received two injections before surgery, and the treatment was found to be safe with no serious side effects. After a year, half of the treated cats were still cancer-free, showing promise for this approach in preventing cancer recurrence. This suggests that gene therapy could be a helpful option for cats battling fibrosarcomas.
People also search for: cat fibrosarcoma treatment · feline cancer gene therapy · why does my cat have a tumor · cat cancer recurrence prevention
Abstract
Despite aggressive pre- or postoperative treatment, feline fibrosarcomas have high recurrence rates. Immunostimulatory gene therapy is a promising approach in veterinary oncology. This phase I dose-escalation study was performed to determine toxicity and feasibility of gene therapy with feline granulocyte-macrophage colony-stimulating factor (feGM-CSF) in cats with fibrosarcomas. Twenty cats were treated with plasmid coding for feGM-CSF attached to magnetic nanoparticles in doses of 50, 250, 750 and 1250 microg. Two preoperative intratumoral injections followed by magnetofection were given. Four control cats received only surgical treatment. Adverse events were recorded and correlated according to the veterinary co-operative oncology group toxicity scale. An enzyme-linked immunosorbent assay was performed to detect plasma feGM-CSF concentrations. No significant treatment related toxicity was observed. Preliminary recurrence results were encouraging as, on day 360, ten of 20 treated cats were recurrence-free. In conclusion, 1250 microg of feGM-CSF plasmid DNA applied by magnetofection is safe and feasible for phase II testing.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/18338834/